Mother's delight as gene therapy offers hope to three-year-old
Children with aromatic l-amino acid decarboxylase (AADC) deficiency find it difficult to control their head, blood pressure and heart rate.
But after receiving the new gene therapy, called Upstaza, Gunreet has made progress that her mother thought would never be possible, such as new movements and vocalising.
It is hoped that she will make further strides as she ages.
Gunreet, from Hayes in west London, was nine months old when she was diagnosed with the condition.
She received the treatment in February 2024 at the world-renowned Great Ormond Street children's hospital (GOSH), which is the only hospital in the UK offering the treatment to children.
Sandeep Kaur said Gunreet has made 'great progress' since her treatment.
'When Gunreet was about seven months old I noticed she wasn't reaching her milestones at the same age that her older brother did,' she said.
'She couldn't hold her own head up or reach out for items. She cried a lot and always wanted to be held.
'Since having the gene therapy, Gunreet has made great progress.
'She cries less, smiles more, and can reach for objects.
'She can hold her head up and is trying to sit up, she's recently learned how to roll from her stomach to her back which is fantastic to see.
'It means a lot to me that Gunreet was able to have this gene therapy – her general health has improved, she has more co-ordination, she can bring her palms together and is able to move her hand to her mouth.'
AADC deficiency is caused by a mutation in the gene that produces the AADC enzyme, this enzyme is needed to produce a neurotransmitter called dopamine which is important in controlling movement.
People with AADC deficiency do not have a working version of the enzyme, which means that they have little or no dopamine in the brain.
This means that they can suffer developmental delays, weak muscle tone and inability to control the movement of the limbs. It can also lead to painful episodes for affected children.
The condition is rare and often deadly, with many children with AADC deficiency not reaching adulthood.
The medicine, also known as eladocagene exuparvovec, consists of a virus that contains a working version of the AADC gene.
The treatment is delivered by millimetre precision to an exact location in the brain of the patient by a team of medics assisted by a robotic surgery tool.
When given to the patient, it is expected that the virus will carry the AADC gene into nerve cells, enabling them to produce the missing enzyme.
This is expected to enable the cells to produce the dopamine they need to work properly, which will improve symptoms of the condition.
It is the first NHS England commissioned gene therapy in the UK infused directly into the brain.
Professor Manju Kurian, consultant paediatric neurologist at GOSH, said 'AADC deficiency is a rare condition but often a cruel one that has such a profound impact on children and their carers and families.
'We know children with the condition have painful episodes that can last for hours and, as their condition progresses, their life becomes more and more difficult.
'It's incredible to me that I can now prescribe novel gene therapies just as I would prescribe paracetamol and antibiotics.
'While the treatment is now available under the NHS at GOSH, we can only do this by working collaboratively across teams inside and outside the hospital, from physios and surgeons to dietitians and speech therapists, alongside partnerships with companies who supply these therapies.
'It's great to see how this treatment has been able to help babies and children across the country like Gunreet.
'The natural history of the condition is that most patients cannot fully hold their head or make any developmental progress after that milestone.
'Gunreet's progress over the last year has been really impressive in that context, as well as the virtual disappearance of the eye crises.
'We're hopeful that one day she will be able to talk or walk, as seen in some of the young patients treated in the clinical trial.'
Professor James Palmer, NHS medical director for specialised commissioning, said: 'This is wonderful news for Gunreet and her family, and a powerful example of how these commitments are translating into real improvements in people's lives.
'By bringing cutting-edge medicines like eladocagene exuparvovec into the health service and setting up our expert clinical teams to successfully deliver them, the NHS is making clear its commitment to improving care through innovation.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
5 hours ago
- The Guardian
Three million on NHS England waiting lists have had no care since GP referral
Almost half of the 6 million people needing treatment from the NHS in England have had no further care at all since joining a hospital waiting list, new data reveals. Previously unseen NHS England figures show that 2.99 million of the 6.23 million patients (48%) awaiting care have not had either their first appointment with a specialist or a diagnostic test since being referred by a GP. The Patients Association described the situation as 'an invisible waiting list crisis' that was 'staggering' in scale, with millions living in limbo, anxious as their health deteriorates. The data raises doubts about Keir Starmer's repeated pledge that 92% of patients will be treated within 18 weeks of referral by 2029 – his key promise to voters on health. The target has not been hit since 2015, and in May just 61% were treated on time. In a further sign of how difficult it will be to meet that target, the data shows that a third of the 3 million unseen patients – 1 million people – have already waited more than 18 weeks without receiving any care. It is the first time the phenomenon of 'unseen patients' has emerged as part of the huge challenge facing the government in its drive to 'get the NHS back on its feet'. Until now debate around the NHS backlog has focused on the number of treatments patients are due to receive and how many are waiting – currently 7.36m and 6.23m respectively. 'If accurate, 3 million people are trapped in an invisible waiting list crisis, stuck without basic diagnostic tests of first appointments while their conditions worsen,' said Rachel Power, the chief executive of the Patients Association. 'The scale is staggering, as nearly half of all patients on a waiting list haven't been seen by anyone. That's not a healthcare service; that's a breakdown. 'These aren't just statistics. They're people checking their phones daily for hospital calls that never come, unable to plan their lives while their symptoms deteriorate.' The figures have been collated and analysed by the health data specialist MBI Health, which helps dozens of NHS trusts improve their treatment waiting times. It has shared its findings with the Guardian. Barry Mulholland, the firm's founder and a former NHS manager, said the health service should see the waiting list as 'a frontlog, not a backlog', because so many people had not had their 'first clinical contact' after joining it. In recent years ministers and NHS bosses have made reducing the number of people waiting 12 or 18 months for care their priority. 'There are so many people who have already waited so long without seeing anyone – 3 million unseen patients who haven't had their first contact. 'Unless that's dealt with, you will never achieve that target of seeing and treating patients within 18 weeks. 'From the government's point of view, the pledge to get back to 18 weeks by 2029 will be really hard to accomplish if this huge group of patients isn't seen more quickly.' 'We'll never clear the waiting list if we don't fix the point where patients enter the system, and long delays begin,' he added. Sign up to Headlines UK Get the day's headlines and highlights emailed direct to you every morning after newsletter promotion NHS England acknowledged the vast number of people who had had no NHS care since joining the waiting list. Of the 7.3m treatments patients were waiting for, 4.7m – nearly two-thirds (64%) – were for people who had not had a first consultation with a specialist or a diagnostic test yet. And 1.6m of this 4.7m had already gone beyond the 18-week supposed maximum waiting time for treatment, it added. Alison Bennett, a Liberal Democrat health spokesperson, said: 'These figures are harrowing. Behind every one of these numbers is a person in pain, anxious about their health, and desperately waiting for their first contact from a clinician. 'This isn't a problem that appeared overnight; it's the direct result of the Conservative party mismanaging our NHS for years. It is unacceptable that millions of people are still being left in a state of limbo, while their conditions potentially worsen.' Ministers would only 'fix' the NHS if they overhauled social care to unblock jammed-up hospitals, she added. MBI's analysis also found that the medical specialities with the largest number of unseen patients were ear, nose and throat care, orthopaedics, eye care, gastroenterology and gynaecology. Between 67% and 75% of those waiting lists are made up of such patients, Mulholland added. The Department of Health and Social Care did not comment on the 3 million unseen patients. A spokesperson said only that: 'Thanks to this government's record investment, reforms and the hard work of NHS staff, we've cut the waiting list by over 260,000 since July 2024, which also fell for the first time in 17 years in April and May outside the pandemic. On top of this, we have also delivered 4.6m appointments – more than double the 2m we promised. 'This government is delivering the fundamental reform needed to turn our NHS around, and our 10-year health plan will build on this progress, to ensure we meet our target that 92% of patients wait no longer than 18 weeks for treatment by March 2029.'
Daily Mail
11 hours ago
- Daily Mail
Huge Parkinson's breakthrough - pioneering treatment helped man go from struggling to make a cup of tea to walking normally thanks to revolutionary drug - a year on, it's STILL working
Incredible footage reveals how one man's life has been transformed after taking a breakthrough drug which curbs debilitating Parkinson's tremors. The clip, shared by the NHS, shows how taking Produodopa has transformed 52-year-old Damien Gath's life. At the start of the video, Damien, who was diagnosed with Parkinson's disease just over 12 years ago, struggles to make a cup of tea due to his tremors. A voice over explains: 'In 2024, he started a revolutionary new treatment to manage his symptoms.' The video then shows him, 'just two days later' making a cup of tea and this time the improvement was extraordinary'. Now, they continued: 'Nine months on, Damian has a renewed sense of purpose, is back at work, and is sharing his experiences, and fighting the progression of Parkinson's.' 'It's been extraordinary and life-changing—the massive difference is that there are now no fluctuations,' said Mr Gath. The end of the clip even incredibly shows Mr Gath at a gym, now able to do a fitness workout. View this post on Instagram A post shared by NHS England (@nhsengland) In the comment section, social media users were left stunned by his impressive transformation. One user wrote: 'What a difference!! Now these are the NHS stories I love hearing about!! Wishing him all the very best.' Another user commented: 'Science is magic.. This is incredible to witness. May more breakthroughs change more lives.' Meanwhile a third user wrote: 'This is phenomenal for this man. Amazing.' The key to this incredible transformation lies in a black rectangular device worn on Damien—a portable pump that slowly releases a drug called foslevodopa- foscarbidopa (or Produodopa). It works increasing the amount of a hormone called dopamine in the brain, which is involved with movement and mood. In Parkinson's disease, which affects 145,000 Brits, brain cells responsible for making the hormone die off, leading to a deficiency. While other medicines are currently available, patients with severe disease often have to a concoction of several pills to feel relief. Many find that their symptoms worsen in the evening once the effect of the medication has worn off. But the Produodopa infusion delivers a steady stream of medicine throughout the day and night, entering the patient's bloodstream through a cannula under the skin that is controlled by a small, automatic pump. Mr Gath was one of the first patients at NHS Sherwood Forest Hospitals Trust to receive what he called a life-changing medication, which costs the NHS £31,000 per person, per year. Speaking to the Daily Mail, Dr Rob Howard, a professor of Old Age Psychiatry at University College London said, while it can improve symptoms and control them for a longer time 'it can't reverse the disease'. This is because, he explained: 'In Parkinson's, nerve cells die in a part of the brain that produces a neurotransmitter, dopamine, that controls movement. 'Drug treatments like this can help replace the levels of dopamine to compensate for the loss of brain cells and this improves the control of symptoms. 'This can give the appearance of "reversing" Parkinson's, but unfortunately, we still don't have any treatments that slow or stop the death of important nerve cells that cause the disease.' Parkinson's is a disease in which parts of the brain become progressively damaged over years. This leads to people suffering from tremors and stiff and inflexible movements that can eventually rob them of their independence. Patients can also, as a consequence of their disease, suffer from other problems like depression and anxiety. What triggers the brain changes that lead to Parkinson's is unknown and while there are treatments available there is no cure. Patients can also respond differently to treatments — some find drugs offer a solution whereas for others they fail to work. In Mr Gath's case his condition had deteriorated, and he was on a cocktail of four medications six times a day to try and bring his involuntary movements under control. But these had mixed success, and he particularly suffered at night when the dosage began to wear off. However, thanks to the new portable pump he said he is now resting much better. 'I am also sleeping much better, and the duvet doesn't feel like a ton weight on my legs—I can turn over when I want to,' he previously said.
Daily Mail
a day ago
- Daily Mail
Revealed: The top baby names in England and Wales with a 23% rise in Muhammad as it takes number one spot for second year in a row
Yusuf Mahmud Nazir died from respiratory failure, pneumonia and tonsillitis in November 2022 - just eight days after he was seen at Rotherham Hospital and sent home with antibiotics. After his family rejected a previous report branding the child's care 'appropriate', a new publication by NHS England has finally confirmed little Yusuf was failed by the health service. His uncle Zaheer Ahmed broke down in tears today as he said his nephew was failed before developing multi-organ failure and suffering several cardiac arrests. 'Despite all these failings, despite all these issues that we've had, we still do not know how Yusuf has died. We want answers. We want an inquest. An inquest will tell us how Yusuf has died. And this is what the family are demanding,' he said.
